Login
$ZBIO
$27.93 -$0.08 (0.29%) Live

$ZBIO SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
06 Nov 2026 8-K: Other Events

We have acted as counsel to Zenas BioPharma, Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3ASR (the “Registration Statement”) filed on October 8, 2025 by the Company with the Secur...

06 Nov 2026 424B5
05 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

- PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 -

27 Oct 2026 SCHEDULE 13G
13 Oct 2026 8-K: Regulation FD Disclosure

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

11 Sep 2026 S-3ASR
11 Sep 2026 FORM S-8
08 Sep 2026 SCHEDULE 13G
08 Sep 2026 Form 3: InnoCare Pharma Inc., 10% owner

Holds 7,000,000 shares of Common Stock

08 Sep 2026 SCHEDULE 13G/A
02 Sep 2026 Form 4: Oliger Christy J., Director

Granted 37,000 Stock Option (Right to Buy)

02 Sep 2026 Form 3: Oliger Christy J., Director

No securities owned

19 Aug 2026 SCHEDULE 13D/A
19 Aug 2026 144
17 Aug 2026 SCHEDULE 13D/A
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 -

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support